Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.
Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, Cortés J.
Carey LA, et al. Among authors: delaney r.
NPJ Breast Cancer. 2022 Jun 9;8(1):72. doi: 10.1038/s41523-022-00439-5.
NPJ Breast Cancer. 2022.
PMID: 35680967
Free PMC article.